Demography and patient characteristics at enrolment
| Atorvastatin + tofacitinib 10 mg bid (N=50) | Placebo + tofacitinib 10 mg bid (N=47) | |
|---|---|---|
| Female, n (%) | 45 (90) | 42 (89.4) |
| White, n (%) | 20 (40) | 22 (46.8) |
| Asian, n (%) | 25 (50) | 18 (38.3) |
| Age in years, mean (SD) | 51.5 (11.7) | 52.6 (11.4) |
| History of herpes zoster, n (%)* | 2 (4.0) | 1 (2.1) |
| LDL-cholesterol, mean (SD) mmol/l | 2.90 (0.78) | 2.97 (0.79) |
| In US patients, mean (SD) mmol/l | 2.97 (0.82) | 3.07 (0.89) |
| In Korean patients, mean (SD) mmol/l | 2.83 (0.75) | 2.79 (0.55) |
| HDL-cholesterol, mean (SD) mmol/l | 1.42 (0.39) | 1.46 (0.37) |
| In US patients, mean (SD) mmol/l | 1.35 (0.41) | 1.42 (0.37) |
| In Korean patients, mean (SD) mmol/l | 1.50 (0.36) | 1.52 (0.37) |
| Total cholesterol, mean (SD) mmol/l | 4.91 (1.02) | 5.09 (0.89) |
| In US patients, mean (SD) mmol/l | 5.00 (1.05) | 5.16 (1.00) |
| In Korean patients, mean SD) mmol/l | 4.82 (0.99) | 4.97 (0.67) |
| Tender joints (of 68 joints counted), mean (SD) | 23.2 (18.2) | 21.4 (14.8) |
| Swollen joints (of 66 joints counted), mean (SD) | 16.9 (12.7) | 15.3 (11.3) |
| CRP, mean (SD) mg/l | 33.2 (38.2) | 22.3 (27.0) |
| HAQ-DI, mean (SD) | 1.5 (0.74) | 1.5 (0.74) |
| DAS28-4(ESR), mean (SD) | 6.5 (1.3) | 6.5 (1.1) |
*No patients had herpes zoster at study start.
bid, twice daily; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; HAQ-DI, health assessment questionnaire–disability index; HDL, high-density lipoprotein; LDL, low-density lipoprotein.